<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1048">
  <stage>Registered</stage>
  <submitdate>27/01/2006</submitdate>
  <approvaldate>27/01/2006</approvaldate>
  <nctid>NCT00283959</nctid>
  <trial_identification>
    <studytitle>A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease</studytitle>
    <scientifictitle>A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AA1565521 (FAB-CL-202)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fabry Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AT1001 (migalastat hydrochloride)

Experimental: 150 mg capsule - oral migalastat HCl (AT1001) administered every other day.


Treatment: drugs: AT1001 (migalastat hydrochloride)
administered every other day

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary: Safety and tolerability.</outcome>
      <timepoint>All visits</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary: Pharmacodynamic and functional (cardiac, CNS/PNS, and renal) parameters.</outcome>
      <timepoint>All visits</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males between 18 and 65 years of age (inclusive)

          -  Hemizygous for Fabry disease

          -  Have a confirmed diagnosis of Fabry disease with a documented missense gene mutation
             (individual or familial)

          -  Have enhanceable enzyme activity based on in vitro tests

          -  Have documented evidence of cardiac and/or renal dysfunction (e.g., abnormal ECG, left
             ventricular hypertrophy, renal insufficiency)

          -  Must be previously untreated by ERT or substrate depletion for Fabry disease and be
             willing to undergo two kidney, two cardiac, and three skin biopsies

          -  Agree to be sexually abstinent or use a condom with spermicide when engaging in sexual
             activity during the course of the study and for a period of 30 days following their
             completion of the study

          -  Willing and able to sign an informed consent form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of significant disease other than Fabry disease

          -  History of organ transplant

          -  Serum creatinine greater than 1.5 mg/dL on Day -2

          -  Screening 12-lead ECG demonstrating QTc &gt; 450 msec prior to dosing

          -  Pacemaker or other contraindication for MRI scanning

          -  Taking a medication prohibited by the protocol: Fabrazyme (agalsidase beta), Replagal
             (agalsidase alfa), Glyset (miglitol), Zavesca (miglustat), or any experimental therapy
             for any indication

          -  Participated in a clinical trial in the last 30 days

          -  Any other condition, which, in the opinion of the investigator, would jeopardize the
             safety of the patient or impact the validity of the study results</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>4</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital, Department of Nephrology - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amicus Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to collect information on the safety of AT1001 (migalastat
      hydrochloride) and how AT1001 works in patients with Fabry disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00283959</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Roberto Giugliani, MD, PhD</name>
      <address>Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>